Gilead Sciences, Inc. announced that the China National Medical Products Administration (NMPA) has approved a pre-exposure prophylaxis indication for Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg,FTC/TDF). In China, Truvada for PrEP is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 in at-risk adults and adolescents weighing at least 35 kg.
Gilead Sciences, Inc. announced that the FDA approved a pre-exposure prophylaxis (PrEP) indication for Descovy (emtricitabine 200 mg and tenofovir...
Norgine announced positive top line results for its phase III study, NOCT, a multicentre, randomised, parallel-group clinical trial comparing the...
Gilead Sciences, Inc. announced that it will donate Truvada for PrEP (emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg...
For colonic lavage prior to diagnostic examination or surgical procedures requiring a clean colon, e.g. colonoscopy, barium enema or colonic resection.
Gilead Sciences, Inc. announced results of a retrospective nationwide analysis of the impact of Truvada (emtricitabine 200 mg and tenofovir...
Gilead Sciences' Canada has filed a supplemental marketing application with Health Canada seeking approval for Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg tablets)
The National Institute for Health and Care Excellence (NICE) has published a survey of evidence for the use of Truvada...